In a double-blind, placebo-controlled, randomised phase II study that enrolled 134 non-squamous, heavily pretreated (≥3 lines) NSCLC patients unselected for RET rearrangements, lenvatinib (24 mg once daily) plus best supportive care (BSC) improved OS (38.4 vs. 24.1 weeks, p = 0.065), PFS (20.9 vs. 7.9 weeks, p < 0.001) and ORR (10.1% vs. 2.2%) compared with BSC [36]. This evidence concerns the gene RET and non-small cell lung carcinoma.